Crucell (ticker: CRXL) makes a tumble after it was announced that Wyeth no longer is interested in taking over the Dutch biopharma company. This news comes after the recent announcement dated from 8th January. Now Wyeth became itself a takeover target, the deal is put on hold.
As Big Pharma continues to feel the pain with blockbusters going off patent, they subsequently find themselves with a need to buy revenues to fill the gap through biotechs. There exists a Biotech ETF Long (ticker: XBI).
Sphere: Related Content
As Big Pharma continues to feel the pain with blockbusters going off patent, they subsequently find themselves with a need to buy revenues to fill the gap through biotechs. There exists a Biotech ETF Long (ticker: XBI).
No comments:
Post a Comment